Therapeutic targeting of circ CUX1/EWSR1/MAZ axis inhibits glycolysis and neuroblastoma progression
Aerobic glycolysis is a hallmark of metabolic reprogramming in tumor progression. However, the mechanisms regulating glycolytic gene expression remain elusive in neuroblastoma (NB) the most common extracranial malignancy in childhood. Herein, we identify that CUT like homeobox 1 (CUX1) and CUX1 generated circular RNA (circ CUX1) contribute to aerobic glycolysis and NB progression. Mechanistically, p110 CUX1, a transcription factor generated by proteolytic processing of p200 CUX1, promotes the expression of enolase 1, glucose 6 phosphate isomerase, and phosphoglycerate kinase 1, while circ CUX1 binds to EWS RNA binding protein 1 (EWSR1) to facilitate its interaction with MYC associated zinc finger protein (MAZ) resulting in transactivation of MAZ and transcriptional alteration of CUX1 and other genes associated with tumor progression. Administration of an inhibitory peptide blocking circ CUX1 EWSR1 interaction or lentivirus mediating circ CUX1 knockdown suppresses aerobic glycolysis, growth, and aggressiveness of NB cells. In clinical NB cases, CUX1 is an independent prognostic factor for unfavorable outcome, and patients with high circ CUX1 expression have lower survival probability. These results indicate circ CUX1/EWSR1/MAZ axis as a therapeutic target for aerobic glycolysis and NB progression.
EMBO molecular medicine